

Hope. Now within reach.

Aiming to reach a billion
patients worldwide with
affordable, lifesaving
medicines



Fact Sheet

Enabling Global Health Equity

As a global frontrunner in the biopharmaceuticals industry, the Biocon Group has dedicated itself to providing high-quality, cost-effective medicines to patients around the world.










Biocon, with its key business verticals of Generics, Biosimilars, and Research Services, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.

Biocon has been significantly impacting patients' health, while creating exponential and enduring value for all its stakeholders for over 45 years.

The Group is guided by a strong sense of purpose to enable health equity worldwide by providing affordable access to essential and lifesaving therapeutics.

Cutting-edge science, large-scale manufacturing capacity and a global commercial footprint allow Biocon to make essential medicines accessible to patients worldwide, at affordable price points. At the same time, the Group entities are efficiently deploying capital and optimizing resources to make an enduring impact on the health of patients, the planet, and the business.


BIOCON GROUP: QUICK FACTS

-  Bengaluru, India  Employees: **16,300+**
-  Commercial reach: **120+ countries**
-  Patents: **1,700+**
-  Biosimilars commercialized globally: **9**
-  Biosimilars in portfolio: **20**
-  APIs in portfolio: **50+**
-  Generic Formulations in portfolio: **60+**
-  Syngene's client base: **400+**

FY2024 - FINANCIAL HIGHLIGHTS

-  Annual revenue: **₹156,212 mn (\$1.9 bn)**
-  EBITDA: **₹41,642 mn**
-  EBITDA margin: **27%**
-  Annual profit: **₹10,225 mn**
-  Gross R&D spend: **₹11,614 mn**

FY2024 - REVENUE BREAK-UP



Our Vision

- To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners, and healthcare systems across the globe.

Our Values

- Value creation through innovation and differentiation.
- Quality through compliance and best practices.
- Integrity and ethical behavior.
- Collaboration, teamwork and mutual respect.
- Performance-driven work culture.

BIOCON IS DELIVERING ON ITS VISION THROUGH ITS THREE PRINCIPAL BUSINESSES.

Generics Business

Ensuring Access through Quality, Affordability, Reliability

The Group's Generics vertical, managed by **Biocon Limited**, is dedicated to manufacturing and supplying affordable generic bulk drugs and finished formulations. The Generics business comprises a growing portfolio of Active Pharmaceutical Ingredients (APIs) as well as finished dosages.

Biocon is the leading global manufacturer of statin and immunosuppressant APIs. Biocon forayed into generic formulations in 2013, with a strategy to forward integrate its in-house, complex and differentiated APIs and move up the value chain, ensuring reliability of quality and supply to its customers and patients.

The APIs pipeline includes 50+ products, spanning cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules which has been further augmented to include oncology-based Highly Potent APIs (HPAPIs) and peptides, particularly Glucagon-like peptide-1 receptor agonists (GLP-1s), that address diabetes and weight management and serve 750+ pharma companies across 100+ countries.

The Generics business launched generic Liraglutide for diabetes and obesity in the U.K. in February 2025 following approval from MHRA, UK, in March 2024, making Biocon Limited the first generics company to obtain approval for generic Liraglutide in a major regulated market.

The Generic Formulations portfolio comprises 60+ products across cardiology, oncology, immunology, and autoimmune indications. The company has a long and proud history of maintaining high standards of quality and compliance, having received 90+ cGMP approvals from international regulatory bodies.

Biocon's global commercial strategy combines direct selling, licensing, and partnerships for market expansion.



Biosimilars Business

Transforming Healthcare. Transforming Lives.

Biocon Biologics Limited is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company specializes in developing, manufacturing, and commercializing a differentiated and comprehensive biosimilars portfolio including insulins, monoclonal antibodies and conjugated recombinant proteins.

Biocon Biologics has commercialized nine biosimilars in key Emerging Markets and Advanced Markets like U.S., Canada, Europe, Australia, and Japan. The Company has a portfolio of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. Biocon Biologics has established its credibility as a leading biosimilars player with a proven track record of scientific excellence by achieving many 'firsts' in the biosimilars industry.

The Company ranks among the world's Top 15 biomanufacturing companies in terms of capacity and is among the leading insulin producers worldwide. Adherence to the highest quality standards for biosimilars has led Biocon Biologics to obtain 80+ cGMP approvals from international regulatory agencies.

Following the successful integration of the global biosimilars business acquired from long term partner, Biocon Biologics now has a direct, on-ground commercial presence in the U.S., Canada, 19 European countries, including the Top 5 European markets (Germany, France, UK, Spain, Italy), and 8 Emerging Market countries.



Research Services Business

Putting Science to Work

Syngene International Limited is an integrated research, development, and manufacturing services company catering to various sectors such as pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals.

Syngene's team of over 5,600 scientists possesses the expertise and capability to deliver great science, ensuring robust data security and high-quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb, along with 2 million square feet of specialist discovery, development, and manufacturing facilities, Syngene collaborates with biotech companies and multinationals like GSK, Zoetis, and Merck KGaA, supporting their pursuit of leading-edge science.



Strong ESG Focus

Biocon's corporate culture is anchored in purpose, ethics, and equity. From addressing health disparities to promoting community well-being and environmental stewardship, Biocon's Environmental, Social and Governance (ESG) strategy is aimed at shaping a future where business success and responsibility intertwines with societal progress.

The Group's strategy, which encompasses globally benchmarked policies, processes, and practices, ensures that purpose-inspired responsible business principles and the highest standards of ethics and governance guide its actions. It has integrated responsible business principles not only within the Company but also throughout its value chain. Biocon's approach, rooted in good governance, transparency, and accountability underscores its commitment to long-term sustainable value creation.

Biocon Limited has set itself ambitious targets for reducing its Scope 1 and Scope 2 emissions, lowering freshwater consumption, and ensuring 100% recycling of waste.

Biocon improved its Global ESG Score by 6 points to 69 in the 2024 S&P Corporate Sustainability Assessment. In the S&P Global Sustainability Yearbook 2024, the Company featured for the second year in a row.

Biocon Foundation, the Corporate Social Responsibility (CSR) arm of Biocon Group, has been working in the areas of socio-economic upliftment through programs aimed at improving healthcare access, education opportunities, environmental sustainability, rural and urban civic infrastructure since 2005. The Foundation's comprehensive programs address the myriad developmental challenges facing India by delivering scalable solutions through innovative and sustainable models.

The Foundation has developed and nurtured strong relationships with the local community and other stakeholders. It has also nurtured long-term strategic partnerships with tertiary healthcare providers to get technical support and with governments to fulfil mutual obligations in a public-private partnership (PPP) mode.

The Biocon Academy, founded in 2013, spearheads the Biocon Group's CSR initiatives in technical and professional education for aspiring biotechnologists. The Academy imparts rigorous academic learning and world-class industry-oriented training programs on applied aspects of various life sciences disciplines. In doing so, the Academy is helping create an enabling environment that molds everyone into highly capable, forward-looking self-starters, equipped with the skills, experience and knowledge to move India forward.

ESG FY2024



Women representation in Workforce: **25%**



Corporate Social Responsibility (CSR) spending: **₹315.40 mn**



Beneficiaries of CSR initiatives: **375,000+**



Water recycled/ reused: **70%**



Renewal power utilization: **80%***



Waste disposal through circularity: **79%**



Total Greenhouse Gas (GHG) emissions avoided: **218,758 tCO₂e**

**Biocon Group India Operations*





KEY AWARDS AND RECOGNITIONS



Biocon (including Biocon Biologics)

- Included in S&P's Sustainability Yearbook 2024 for the second consecutive year.
- Named among global sustainability leaders for the third consecutive year in the Dow Jones Sustainability Emerging Markets Index in 2024.
- Selected as a constituent of FTSE4Good Index Series by FTSE Russel.
- Ranked 9th in Science magazine's 2024 list of Top 20 Global Employers in biotech, pharma, and biopharma.
- Ranked among Top 5 India's Most Sustainable Companies in the Pharma & Healthcare sector at BW Businessworld IMSC Awards 2024.

Biocon Limited

- Achieved notable improvement by 6 points on S&P Global's Corporate Sustainability Assessment (CSA) with an ESG Score of 69 in 2024.
- Received Golden Peacock Award for ESG at the 2023 Annual London Global Convention on Corporate Governance & Sustainability, London (UK).
- Won Excellence Award at 37th National Convention on Quality Concept 2023.
- Won Best Procurement Team Award at the Procurement Excellence Summit & Awards 2023.

Biocon Biologics

- Debuted on S&P Global's Corporate Sustainability Assessment with an ESG score of 53 in 2024.
- Received Workplace Occupational Health & Safety and Environment Excellence Award 2024 from World Safety Organization.
- Won EHS Best Practices Global Award at 1st Annual Greentech Global EHS Awards & Summit 2024.
- Received The Asset Triple A Treasuries Awards 2024 for 'Best Solution for Healthcare – Regional' in 'Best Liquidity and Investment Solution' category.
- Won Compliance Team of the Year Award at 4th Edition of Future of Legal and Compliance Summit by UBS Forums.
- Won Company of the Year (Biotech Manufacturing) Trophy at the Sustainability & CSR Malaysia Awards 2024.

Syngene

- Ranked as one of 'India's Best Managed Companies' by Deloitte India.

Biocon Foundation

- Won the prestigious 'Doing Good for Bharat Awards' 2024 in Healthcare category for eLAJ Smart Clinics.
- Recognized for its work in the field of education by Karnataka State Government.
- Won Dalmia Bharat - CSRBOX CSR Impact Award 2023 for Oral Cancer Screening Program.

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon does not assume any obligation to update the information on a frequent basis.

Last Updated: Feb 2025

Biocon Group Key Management Team



Kiran Mazumdar-Shaw
Chairperson, Biocon Group



Peter Bains
Group CEO, Biocon
CEO Designate,
Syngene International Limited



Siddharth Mittal
CEO & Managing Director,
Biocon Limited



Shreehas Tambe
CEO & Managing Director,
Biocon Biologics Limited

Biocon Limited

20th KM, Hosur Road, Electronic City,
Bengaluru, India 560 100

For more information:

Seema Ahuja,
SVP & Global Head of Communications
& Corporate Brands, Biocon Group
Email: Group.Communications@biocon.com

Website: www.biocon.com
Email: info@biocon.com
Twitter: @Bioconlimited
LinkedIn: /company/biocon/
Facebook: @Bioconlimited

Follow us at : 